|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls. | Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD | 2018 | 中华神经外科疾病研究杂志2018，17，4： | 2 |
| 2 | Fr-ontoethmoidal giant cell reparative granuloma显示文摘 | FELSBERG G J TIEN R D MCLENDON R E | 1995 | AJNR Am J Neuroradiol1995，16，： | 1 |
| 3 | 显示文摘 | O'Neil M Marohn J Mclendon G | 1990 | J Phys Chem1990，94，： | 1 |
| 4 | β-amyloid-mediated vasoactivity and vascular endothelial damage 显示文摘 | Thomas T Thomas G Mclendon C | 1996 | Nature1996，380，： | 1 |
| 5 | β-amyloid-mediated vasoactivity and vascular endothelial damage显示文摘 | Thomas T Thomas G Mclendon C | 1996 | Nature1996，380，： | 1 |
| 6 | Microdosimetry of Alpha-particle-emitting 211 At-labeled Monoclonal Antibody(MAb) Using Histological Images of Malignant Brain Tumors 显示文摘 | Akabani G McLendon RE Bigner DD | 2000 | J Nucl Med2000，84，： | 1 |
| 7 | β-Amyloidmediated vasoactivity and vascular endothelial damage显示文摘 | Thomas G McLendon C | 1996 | Nature1996，380，： | 1 |
| 8 | Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds:theoretical analysis显示文摘 | AKABANI G MCLENDON R E BIGNER D D | 2002 | Int J Radiat Oncol Biol Phys2002，54，4： | 1 |
| 9 | Triboelectrostaticseparation of f y ash with different charging materials 显示文摘 | Soong Y Irdi G A Mclendon T R | | Chemical Engineering & Technolog0，30，2： | 1 |
| 10 | Nanoencapsulation of Cytochromec and Horseradish Peroxidase at the Galleries of A-Zirconium Phosphate显示文摘 | Kumar C V McLendon G L | 1997 | ChemMater1997，，9： | 1 |
| 11 | beta-Amyloid-mediated vasoactivity and vascular endothelial damage显示文摘 | Thomas T Thomas G McLendon C | 1996 | Nature1996，380，6570： | 1 |
| 12 | Beta-amyloid me- diated vasoactivity and vascular endothelial damage see com- ments 显示文摘 | Thomas T Thomas G Mclendon C | 1996 | Nature1996，380，： | 1 |
| 13 | Tumor resection cavity administered iodine-131-1abeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects显示文摘 | McLendon RE Akabani G Friedman HS | 2007 | Nuclear Medicine and Biology2007，34，： | 1 |
| 14 | Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against ayngeneic intracerebral glioma显示文摘 | Heimberger AB Crotty LE Archer GE Mclendon RE Frieddman A Dranoff G | 2000 | J Neuroimmunol2000，103，1： | 1 |
| 15 | Femtosecond electron-transfer dynamics at a sensitizing dye-semiconductor (TiO2)interface显示文摘 | REHM J M MCLENDON G L NAGASAWA Y | 1996 | J Phys Chem1996，100，： | 1 |
| 16 | 显示文摘 | Rehm J M Mclendon G L Nagasawa Y | 1996 | Phys Chem1996，100，： | 1 |
| 17 | ThePolitics of State Higher Education Governance Reform显示文摘 | MICHAEL K MCLENDON ERIK G NESS | 2003 | Peabody Journal of Education2003，，4： | 1 |
| 18 | Picosecond measurements of exciton trapping in semiconductor clusters显示文摘 | O′NEIL M MAROHN J McLENDON G | 1990 | Chem Phys Lett1990，168，2： | 1 |
| 19 | Vascular targeted endoradiotherapy of tumors using alpha - particle - emitting compounds: theoretical analysis 显示文摘 | Akahani G Mclendon RE Bigner DD | 2002 | International Journal of Radiation Oncology Biology Physics2002，54，4： | 1 |
| 20 | Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral,specific,EGFR-tyrosine kinase inhibitor ZD1839 (iressa)显示文摘 | Heimberger A B Learn C A Archer G E McLendon R E Chewning T A Tuck F L Pracyk J B Friedman AH Friedman HS Bigner DD Sampson JH | 2002 | Clin Cancer Res2002，8，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员